While last year's American Society of Clinical Oncology (ASCO) meeting ended on cautiously encouraging advances in the cancer immunotherapy space, this year's meeting has put immunotherapy front and center, thanks in part to much-awaited data on and anti-PDL-1 and anti-PD-1 drugs from Roche AG and Bristol-Myers Squibb Co., respectively. (See BioWorld Today, June 6, 2012.)